Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Media Coverage
Our commercial intelligence and analysis are used by the Financial Times, the Wall Street Journal, Forbes, Nature, and Reuters, among others.
Take a look at the latest Evaluate and Vantage coverage. To learn more about how we work with healthcare and business reporters worldwide, or if you are looking for specific data and expert insights to support a current story, please contact us.
Latest Media Coverage
Nature Reviews Drug Discovery
FDA new drug approvals in Q1 2020
In a quarter that was marked by the rapid spread of the COVID-19 pandemic, drug approvals continued (Table 1), but launching was a completely different…
New York Times
Pharmaceutical Profits and Public Health Are Not Incompatible
The rapid spread of the coronavirus has revived a decades-old debate over pharmaceutical policy, with both sides doubling down on long-held views.
Nature Reviews Drug Discovery
Top companies and drugs by sales in 2019
Roche is back on top. Over the past few years, the tussle for biopharma’s biggest company by sales has largely been contested by Novartis and Pfizer; but a winning streak…
Browse the archive
PMLive
Biogen under fire over $88,000 Vumerity annual price
Consensus estimates compiled by EvaluatePharma reflect this with forecast sales of Vumerity at a modest $111m in 2024.
Pharmaphorum
Biogen bags FDA okay for Tecfidera follow-up Vumerity
Some analysts think it is likely to be an also-ran in the market, with EvaluatePharma predicting around $110 million in sales in 2024, although others are more…
Handelsblatt
The stock market is discovering gene therapy
"Technologies such as Crispr are highly valued," says a study by the British analysis company EvaluatePharma, "but they also represent a high risk. Any serious setback…
Look back at pharma news in the week to October 25
Look back at pharma news in the week to October 25
The sell-side expects tucatinib to post 2024 sales of $268 million, according to EvaluatePharma consensus.
Neue Zürcher Zeitung
The polycultis of the knee are in enviable form
According to estimates by market research firm Evaluate Pharma, the annual increase in prescription drug sales between 2019 and 2024 will reach almost 7% worldwide.
The Pharma Letter
Look back at pharma news in the week to October 18
EvaluatePharma consensus predicts 2024 palovarotene sales of $357m; there are currently no forecasts for BLU-782, presumably because of its early stage.
Fianze und Wirtschaft
Highly competitive market for cancer drugs
According to an estimate by data service provider EvaluatePharma, about $ 182 billion will be spent on research and development this year, much of it to fight more than…
Nature Reviews Drug Discovery
FDA new drug approvals in Q3 2019
The biggest approval of the third quarter was not a new drug, but an oral version of Novo Nordisk’s semaglutide, branded Rybelsus, which has a consensus sales forecast of…
PMLive
SMC approves Yescarta and Keytruda, rejects Perjeta
This latest approval will allow Keytruda to continue on its upwards trajectory – Evaluate Pharma has forecasted that it will be the top-selling drug worldwide in 2024 at…
PMLive
Novartis bags US okay for Lucentis follow-up Beovu in wet AMD
Analysts think that Beovu has the potential to grow quickly to blockbuster sales levels, with...EvaluatePharma pegging it at a more modest $1.3bn in 2024.
